iBio, Inc. announced an open‑market sale agreement with Jefferies LLC that allows the company to sell up to $100 million of its common stock on the open market. The agreement is part of a $200 million shelf registration that became effective on February 9 2026, giving iBio flexibility to raise capital as needed.
The new agreement follows a $50 million public offering in August 2025 and a $26 million private placement in January 2026. At the end of fiscal year 2025, iBio reported cash, cash equivalents, and debt investments of $52.7 million, and the ATM will extend the company’s runway as it advances obesity and cardiometabolic drug candidates toward clinical milestones.
iBio’s fiscal 2025 results showed a net loss of $18.4 million on revenue of $0.4 million, reflecting the high research and development costs typical of a preclinical biotechnology company. The capital raised will support the development of IBIO‑610 and IBIO‑600, antibody therapies engineered for extended half‑life to enable infrequent dosing.
The company terminated its prior ATM program with Chardan Capital Markets and Craig‑Hallum Capital Group, signaling a shift to a new partner and a streamlined capital‑raising strategy. The new agreement also gives iBio the ability to time sales and manage dilution more effectively.
iBio continues to leverage artificial intelligence and computational biology in its discovery pipeline, positioning itself to compete with GLP‑1 receptor agonists while offering potential benefits such as muscle mass preservation. The ATM reflects the company’s ongoing need for capital to sustain its preclinical program and maintain competitiveness in the obesity and cardiometabolic market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.